Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus FLORONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus FLORONE.
BREO ELLIPTA vs FLORONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Glucocorticoid receptor agonist; induces phospholipase A2 inhibitory proteins (lipocortins), which suppress release of arachidonic acid and subsequent prostaglandin/leukotriene synthesis; also suppresses cytokine production and immune cell migration.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum use: 45 g/week.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life of approximately 2-3 hours; clinical context: duration of action may extend beyond half-life due to tissue binding.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (approximately 80% as metabolites, <5% unchanged), biliary/fecal (remainder).
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid